Published on:

Pay for Delay

The New York Times has an interesting editorial on efforts to put a stop to drug makers paying off generic competition to stay on the sidelines:

The underhanded tactic, known as pay for delay, occurs when a generic drug company tries to bring its product to market by challenging the patents on a brand-name drug. Rather than engage in a costly and unpredictable court battle, the brand-name manufacturer sometimes pays the challenger substantial compensation to delay marketing its drug, and the generic company often welcomes the easy, risk-free money.